: Currently undervalued as it spins off its lower-margin diabetes unit to focus on high-growth surgical tech.

: Offers a high dividend yield (approx. 5.8%) and trades at a forward P/E under 11x following a period of underperformance.

: Regarded by some analysts as one of the most undervalued hyper-growth companies, currently trading at a deep discount to U.S. tech counterparts. High-Yield "Value" Plays

For those seeking stability, these "Dividend Kings" or market leaders are currently being highlighted by major firms like Morningstar and Forbes as having attractive entry points.

: Despite strong performance, some analysts still view it as undervalued relative to its long-term cash flow potential and "Dividend King" status.